PriceTargets.com logo

Sera Prognostics - SERA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $2.75
  • Forecasted Upside: -73.40%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$10.34 As of 04/25/2024 01:00 AM ET
▲ +0.3 (2.99%)

This chart shows the closing price for SERA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sera Prognostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SERA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SERA

Analyst Price Target is $2.75
▼ -73.40% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Sera Prognostics in the last 3 months. The average price target is $2.75, with a high forecast of $2.75 and a low forecast of $2.75. The average price target represents a -73.40% upside from the last price of $10.34.

This chart shows the closing price for SERA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 contributing investment analysts is to moderate buy stock in Sera Prognostics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2023William BlairReiterated RatingOutperformLow
8/16/2023William BlairReiterated RatingOutperformLow
8/10/2023CitigroupLower TargetNeutral ➝ Neutral$3.75 ➝ $2.75Low
11/10/2022William BlairReiterated RatingOutperformLow
11/10/2022CitigroupLower TargetNeutral$3.00 ➝ $1.50Low
8/29/2022OppenheimerLower TargetOutperform$17.00 ➝ $11.00Low
8/15/2022CitigroupBoost Target$3.00Low
7/18/2022OppenheimerReiterated RatingOutperform$17.00Low
4/27/2022Berenberg BankInitiated CoverageBuyHigh
3/30/2022CitigroupDowngradeBuy ➝ NeutralHigh
11/18/2021OppenheimerInitiated CoverageOutperform$19.00Low
8/9/2021William BlairInitiated CoverageOutperformLow
8/9/2021CowenInitiated CoverageOutperformMedium
8/9/2021CitigroupInitiated CoverageBuy$18.00Medium
(Data available from 4/25/2019 forward)

News Sentiment Rating

1.36 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/26/2024
  • 8 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 8 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Sera Prognostics logo
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $10.34
Low: $9.77
High: $10.35

50 Day Range

MA: $9.42
Low: $8.47
High: $11.25

52 Week Range

Now: $10.34
Low: $1.52
High: $11.32

Volume

73,664 shs

Average Volume

225,706 shs

Market Capitalization

$335.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Sera Prognostics?

The following Wall Street analysts have issued research reports on Sera Prognostics in the last twelve months: Citigroup Inc., and William Blair.
View the latest analyst ratings for SERA.

What is the current price target for Sera Prognostics?

1 Wall Street analysts have set twelve-month price targets for Sera Prognostics in the last year. Their average twelve-month price target is $2.75, suggesting a possible downside of 73.4%. Citigroup Inc. has the highest price target set, predicting SERA will reach $2.75 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $2.75 for Sera Prognostics in the next year.
View the latest price targets for SERA.

What is the current consensus analyst rating for Sera Prognostics?

Sera Prognostics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SERA.

What other companies compete with Sera Prognostics?

Other companies that are similar to Sera Prognostics include CareDx, Biodesix, Celcuity, Castle Biosciences and Co-Diagnostics. Learn More about companies similar to Sera Prognostics.

How do I contact Sera Prognostics' investor relations team?

The company's listed phone number is 801-990-0520 and its investor relations email address is [email protected]. The official website for Sera Prognostics is www.seraprognostics.com. Learn More about contacing Sera Prognostics investor relations.